Astrazeneca injects $2bn to boost US manufacturing capabilities November 24, 2025 FTSE 100 giant Astrazeneca plans to invest $2bn into growing its manufacturing footprint in Maryland, as part of its efforts to boost its US capabilities and presence. The investment will support the “significant expansion” of its biologics manufacturing facility in Frederick, doubling its capacity and increasing its medicine supply, as well as the construction of [...]
Autumn Budget: Reeves must cure British ‘pessimism’ disease November 5, 2025 Ahead of the Autumn Budget, City Reporter Samuel Norman sits down with top industry names for a Budget Briefing. This week, chief executive of Peel Hunt urges Reeves to use the Budget to start the cure for British pessimism. As Rachel Reeves ruminates over which tax prescription to write to fill her fiscal black hole, [...]
Scrap stamp duty on shares or risk FTSE 100 exodus, Peel Hunt warns October 24, 2025 The government must scrap stamp duty taxed on share trades or risk a growing number of firms quitting London for the New York Stock Exchange, investment bank Peel Hunt has warned. As much as £200m is already set to be lost from government tax receipts by the decision of Astrazeneca, the FTSE 100’s largest constituent, [...]
Astrazeneca vows to lower US medicine prices after pressure from Trump October 13, 2025 Astrazeneca has bowed to pressure from US president Donald Trump to lower the cost of its medicines for patients in America. The Cambridge-based pharma giant said it will provide direct-to-consumer sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80 per cent off list prices, alongside participating in the [...]
Ministers planning drug pricing shake-up to stem pharma exodus October 8, 2025 Ministers are drawing up a radical overhaul of NHS spending rules in a bid to shore up the UK’s world-leading life sciences industry after a string of pharma giants cancelled major UK investment projects. In what would amount to one of the largest shake-ups of NHS drug purchasing rules in recent history, the Prime Minister [...]
GSK shares rally as chief Emma Walmsley to exit after eight years September 29, 2025 The chief executive of pharmaceutical giant GSK has announced plans to step down from the company at the end of the year. Emma Walmsley, who took the helm of the drugmaker in 2017, will be replaced by chief commercial officer Luke Miels. Miels – the former Executive Vice President of Astrazeneca – also joined the [...]
UK drug prices necessary to stop feud with companies, says science minister September 25, 2025 The price the NHS pays for medicines will need to rise to end the feud with pharmaceutical companies and stop the exodus of investment in the UK, science minister Patrick Vallance has said. Lord Vallance told the Financial Times that “all options” were on the table in terms of UK drug pricing, after several large [...]
Why is the pharmaceutical industry turning its back on the UK? September 18, 2025 Since coming into power last year, Rachel Reeves and Keir Starmer have consistently stressed the importance of the life science sector to the UK economy, viewing it as critical for growth. In its aim to boost the industry’s standing, Labour pledged to make the UK an attractive place for investment and innovation, and to increase [...]
GSK plots $30bn investment into US in latest blow to UK’s pharma sector September 17, 2025 GSK has unveiled a new plan to spend $30bn (£22bn) on research and manufacturing facilities in the US. The London-based business said the capital would be deployed over the next five years and would create hundreds of high-skilled American jobs in areas such as AI and advanced digital technologies. The investment of £4.4bn per year [...]
Big pharma’s devastating retreat from the UK September 16, 2025 Merck and AstraZeneca’s withdrawal from UK investment is a warning signal to Rachel Reeves – but is she listening? Asks Oliver Dean Both AstraZeneca and Merck’s decision to abandon their respective UK expansions is more than a corporate setback. It is a catastrophic loss of jobs, investment and future innovation and the public are now [...]